Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.

NCT07201688 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

890

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: rhTNK-tPA
DRUG: Placebo

Sponsor

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.